RocheRoche has reported that its selective estrogen receptor degrader (SERD), giredestrant, has demonstrated significant clinical benefit in pivotal Phase III trials for adjuvant early-stage ER-positive, HER2-negative breast cancer, as well as strong efficacy in advanced breast cancer settings. These results position giredestrant as the first oral SERD to show meaningful clinical benefit in this indication. The announcement sparked a notable 7% jump in Roche’s share price in a single day.
Tag Archive for: Breast Cancer
Marcus Krauss - stock.adobe.com Data on the primary endpoint of BioNTech’s/Duality Biologics’ pivotal Phase III study of its HER2 antibody-drug conjugate BNT323/DB-1303 are not yet public, However, BioNTech says that progression-free survival is better than with Roche’s second-line breast cancer therapy Kadcyla.
https://doi.org/10.3390/ijms241411791Genentech, the US subsidiary of Swiss pharmaceutical giant Roche AG, has strengthened the company’s breast cancer pipeline by pre-licensing the global commercialisation rights to Regor Therapeutics’ RGT-419B for US$850m.